Atomic structures of fibrillar segments of hIAPP suggest tightly mated β-sheets are important for cytotoxicity

eLife

Volumn 6, Issue , 2017, Pages

  Krotee, Pascal ^a,b,c   Rodriguez, Jose A ^a,b,c   Sawaya, Michael R ^a,b,c   Cascio, Duilio ^a,b,c   Reyes, Francis E ^d   Shi, Dan ^d   Hattne, Johan ^d   Nannenga, Brent L ^d   Oskarsson, Marie E ^e   Philipp, Stephan ^f   Griner, Sarah ^a,b,c   Jiang, Lin ^a,b   Glabe, Charles G ^f,g   Westermark, Gunilla T ^e   Gonen, Tamir ^d   Eisenberg, David S ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e UPPSALA UNIVERSITY   (Sweden)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; CASPASE 3; CASPASE 7; THIOFLAVINE; AMYLOID;

ANIMAL CELL; ARTICLE; BETA SHEET; CELL CULTURE; CONTROLLED STUDY; CRYSTALLIZATION; CYTOTOXICITY; DOT HYBRIDIZATION; ELECTRON DIFFRACTION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; MTT ASSAY; NONHUMAN; PANCREAS ISLET BETA CELL; TRANSMISSION ELECTRON MICROSCOPY; CELL SURVIVAL; CHEMISTRY; CRYOELECTRON MICROSCOPY; DRUG EFFECTS; PHYSIOLOGY;

AMYLOID; CELL SURVIVAL; CELLS, CULTURED; CRYOELECTRON MICROSCOPY; HUMANS; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; PROTEIN CONFORMATION, BETA-STRAND;

EID: 85009477015     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.19273     Document Type: Article

References (108)

1. Abedini A, Plesner A, Cao P, Ridgway Z, Zhang J, Tu LH, Middleton CT, Chao B, Sartori DJ, Meng F, Wang H, Wong AG, Zanni MT, Verchere CB, Raleigh DP, Schmidt AM, L-h T. 2016. Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics. eLife 5:e12977. doi: 10.7554/eLife.12977 PMID: 27213520
2. Afonine PV, Moriarty NW, Mustyakimov M, Sobolev OV, Terwilliger TC, Turk D, Urzhumtsev A, Adams PD. 2015. FEM: feature-enhanced map. Acta Crystallographica Section D Biological Crystallography 71:646–666. doi: 10.1107/S1399004714028132 PMID: 25760612
3. Ashburn TT, Auger M, Lansbury PT. 1992. The structural basis of pancreatic amyloid formation: isotope-edited spectroscopy in the solid state. Journal of the American Chemical Society 114:790–791. doi: 10.1021/ja00028a073
4. Bedrood S Li Y, Isas JM, Hegde BG, Baxa U, Haworth IS, Langen R. 2012. Fibril structure of human islet amyloid polypeptide. The Journal of Biological Chemistry 287:5235–5241. doi: 10.1074/jbc.M111.327817 PMID: 221 87437
5. Bram Y, Frydman-Marom A, Yanai I, Gilead S, Shaltiel-Karyo R, Amdursky N, Gazit E. 2014. Apoptosis induced by islet amyloid polypeptide soluble oligomers is neutralized by diabetes-associated specific antibodies. Scientific Reports 4:4267. doi: 10.1038/srep04267 PMID: 24589570
6. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. 1999. Biochemical pathways of caspase activation during apoptosis. Annual Review of Cell and Developmental Biology 15:269–290. doi: 10.1146/annurev.cellbio.15.1.269 PMID: 10611963
7. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. 2003. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110. doi: 10.2337/diabetes.52.1.102 PMID: 12502499
8. Cao P, Tu LH, Abedini A, Levsh O, Akter R, Patsalo V, Schmidt AM, Raleigh DP. 2012. Sensitivity of amyloid formation by human islet amyloid polypeptide to mutations at residue 20. Journal of Molecular Biology 421: 282–295. doi: 10.1016/j.jmb.2011.12.032 PMID: 22206987
9. Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. 2010. MolProbity : all-atom structure validation for macromolecular crystallography. Acta Crystallographica Section D Biological Crystallography 66:12–21. doi: 10.1107/S0907444909042073
10. Collaborative Computational Project Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallographica. Section D, Biological Crystallography 50:760–763. doi: 10.1107/S0907444994003112 PMID: 15299374
11. Colletier JP, Laganowsky A, Landau M, Zhao M, Soriaga AB, Goldschmidt L, Flot D, Cascio D, Sawaya MR, Eisenberg D. 2011. Molecular basis for amyloid-beta polymorphism. PNAS 108:16938–16943. doi: 10.1073/pnas.1112600108 PMID: 21949245
12. Connolly ML. 1983. Solvent-accessible surfaces of proteins and nucleic acids. Science 221:709–713. doi: 10.1126/science.6879170 PMID: 6879170
13. Cooper GJ, Leighton B, Dimitriadis GD, Parry-Billings M, Kowalchuk JM, Howland K, Rothbard JB, Willis AC, Reid KB. 1988. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. PNAS 85:7763–7766. doi: 10.1073/pnas.85.20.7763 PMID: 3051005
14. Cooper S, Khatib F, Treuille A, Barbero J, Lee J, Beenen M, Leaver-Fay A, Baker D, Popović Z, Players F. 2010. Predicting protein structures with a multiplayer online game. Nature 466:756–760. doi: 10.1038/nature09304 PMID: 20686574
15. Diederichs K, Karplus PA. 2013. Better models by discarding data? Acta Crystallographica Section D Biological Crystallography 69:1215–1222. doi: 10.1107/S0907444913001121
16. Eisenberg D Jucker M. 2012. The amyloid state of proteins in human diseases. Cell 148:1188–1203. doi: 10.1016/j.cell.2012.02.022 PMID: 22424229
17. Eisenberg DS, Wesson M, Yamashita M. 1989. Interpretation of protein folding and binding with atomic solvation parameters. Chemica Scripta 29A:217–221.
18. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallographica. Section D, Biological Crystallography 60:2126–2132. doi: 10.1107/S0907444904019158 PMID: 15572765
19. Esapa C, Moffitt JH, Novials A, McNamara CM, Levy JC, Laakso M, Gomis R, Clark A. 2005. Islet amyloid polypeptide gene promoter polymorphisms are not associated with type 2 diabetes or with the severity of islet amyloidosis. Biochimica Et Biophysica Acta 1740:74–78. doi: 10.1016/j.bbadis.2005.02.001 PMID: 15878744
20. Gazdar AF, Chick WL, Oie HK, Sims HL, King DL, Weir GC, Lauris V. 1980. Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. PNAS 77:3519–3523. doi: 10.1073/pnas.77.6.3519 PMID: 6106192
21. Goldsbury C, Goldie K, Pellaud J, Seelig J, Frey P, Müller SA, Kistler J, Cooper GJ, Aebi U. 2000. Amyloid fibril formation from full-length and fragments of amylin. Journal of Structural Biology 130:352–362. doi: 10.1006/jsbi.2000.4268 PMID: 10940238
22. Goldsbury CS, Cooper GJ, Goldie KN, Muller SA, Saafi EL, Gruijters WT, Misur MP, Engel A, Aebi U, Kistler J. 1997. Polymorphic fibrillar assembly of human amylin. Journal of Structural Biology 119:17–27. doi: 10.1006/jsbi.1997.3858 PMID: 9216085
23. Griffiths JM, Ashburn TT, Auger M, Costa PR, Griffin RG, Lansbury PT. 1995. Rotational resonance solid-state NMR elucidates a structural model of pancreatic amyloid. Journal of the American Chemical Society 117:3539–3546. doi: 10.1021/ja00117a023
24. Haataja L Gurlo T, Huang CJ, Butler PC. 2008. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocrine Reviews 29:303–316. doi: 10.1210/er.2007-0037 PMID: 18314421
25. Hattne J, Reyes FE, Nannenga BL, Shi D, de la Cruz MJ, Leslie AGW, Gonen T. 2015. MicroED data collection and processing. Acta Crystallographica Section a Foundations and Advances 71:353–360. doi: 10.1107/S2053273315010669
26. Hiddinga HJ Eberhardt NL. 1999. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. The American Journal of Pathology 154:1077–1088. doi: 10.1016/S0002-9440(10) 65360-6 PMID: 10233846
27. Huang CJ, Lin CY, Haataja L, Gurlo T, Butler AE, Rizza RA, Butler PC. 2007. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56:2016–2027. doi: 10.2337/db07-0197 PMID: 17475 933
28. Hull RL, Shen ZP, Watts MR, Kodama K, Carr DB, Utzschneider KM, Zraika S, Wang F, Kahn SE. 2005b. Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 54:2235–2244. doi: 10.2337/diabetes.54.7.2235 PMID: 15983227
29. Hull RL, Watts MR, Kodama K, Shen Z, Utzschneider KM, Carr DB, Vidal J, Kahn SE. 2005a. Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice. AJP: Endocrinology and Metabolism 289:E703–E709. doi: 10.1152/ajpendo.00471.2004
30. Höppener JW Ahrén B, Lips CJ. 2000. Islet amyloid and type 2 diabetes mellitus. The New England Journal of Medicine 343:411–419. doi: 10.1056/NEJM200008103430607 PMID: 10933741
31. Ivanova MI, Sievers SA, Sawaya MR, Wall JS, Eisenberg D. 2009. Molecular basis for insulin fibril assembly. PNAS 106:18990–18995. doi: 10.1073/pnas.0910080106 PMID: 19864624
32. Jack E, Newsome M, Stockley PG, Radford SE, Middleton DA. 2006. The organization of aromatic side groups in an amyloid fibril probed by solid-state 2h and 19f NMR spectroscopy. Journal of the American Chemical Society 128:8098–8099. doi: 10.1021/ja0581898 PMID: 16787049
33. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC. 1996. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. PNAS 93:7283–7288. doi: 10.1073/pnas.93.14.7283 PMID: 8692984
34. Jurgens CA, Toukatly MN, Fligner CL, Udayasankar J, Subramanian SL, Zraika S, Aston-Mourney K, Carr DB, Westermark P, Westermark GT, Kahn SE, Hull RL. 2011. β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. The American Journal of Pathology 178:2632–2640. doi: 10.1016/j.ajpath.2011.02.036 PMID: 21641386
35. Kabsch W. 2010. XDS. Acta Crystallographica. Section D, Biological Crystallography 66:125–132. doi: 10.1107/S0907444909047337 PMID: 20124692
36. Kahn SE, Cooper ME, Del Prato S. 2014. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383:1068–1083. doi: 10.1016/S0140-6736(13)62154-6 PMID: 24315620
37. Kajava AV, Aebi U, Steven AC. 2005. The parallel superpleated beta-structure as a model for amyloid fibrils of human amylin. Journal of Molecular Biology 348:247–252. doi: 10.1016/j.jmb.2005.02.029 PMID: 15811365
38. Kapurniotu A. 2001. Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. Biopolymers 60:438–459. doi: 10.1002/1097-0282(2001)60:6<438::AID-BIP10182>3.0.CO;2-A
39. Kayed R Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG. 2007. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Molecular Neurodegeneration 2:18. doi: 10.1186/1750-1326-2-18 PMID: 17897471
40. Kyte J, Doolittle RF. 1982. A simple method for displaying the hydropathic character of a protein. Journal of Molecular Biology 157:105–132. doi: 10.1016/0022-2836(82)90515-0 PMID: 7108955
41. Laganowsky A, Liu C, Sawaya MR, Whitelegge JP, Park J, Zhao M, Pensalfini A, Soriaga AB, Landau M, Teng PK, Cascio D, Glabe C, Eisenberg D. 2012. Atomic view of a toxic amyloid small oligomer. Science 335:1228–1231. doi: 10.1126/science.1213151 PMID: 22403391
42. Lawrence MC, Colman PM. 1993. Shape complementarity at protein/protein interfaces. Journal of Molecular Biology 234:946–950. doi: 10.1006/jmbi.1993.1648 PMID: 8263940
43. Lee B, Richards FM. 1971. The interpretation of protein structures: estimation of static accessibility. Journal of Molecular Biology 55:379–400. doi: 10.1016/0022-2836(71)90324-X PMID: 5551392
44. Lee SC, Hashim Y, Li JK, Ko GT, Critchley JA, Cockram CS, Chan JC. 2001. The islet amyloid polypeptide (amylin) gene S20G mutation in Chinese subjects: evidence for associations with type 2 diabetes and cholesterol levels. Clinical Endocrinology 54:541–546. doi: 10.1046/j.1365-2265.2001.01244.x PMID: 11318791
45. Lin CY, Gurlo T, Kayed R, Butler AE, Haataja L, Glabe CG, Butler PC. 2007. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. Diabetes 56:1324–1332. doi: 10.2337/db06-1579 PMID: 17353506
46. 2-microglobulin forms three-dimensional domain-swapped amyloid fibrils with disulfide linkages. Nature structural & molecular biology 18:49–55. doi: 10.1038/nsmb.1948 PMID: 21131 979
47. Liu C, Zhao M, Jiang L, Cheng PN, Park J, Sawaya MR, Pensalfini A, Gou D, Berk AJ, Glabe CG, Nowick J, Eisenberg D. 2012. Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates. PNAS 109:20913–20918. doi: 10.1073/pnas.1218792109 PMID: 23213214
48. Liu S, Hattne J, Reyes FE, Sanchez-Martinez S, Jason de la Cruz M, Shi D, Gonen T. 2016. Atomic resolution structure determination by the cryo-EM method MicroED. Protein Science : A Publication of the Protein Society 00:1–8. doi: 10.1002/pro.2989
49. Liu Y Peterson DA, Kimura H, Schubert D. 1997. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. Journal of Neurochemistry 69:581–593. doi: 10.1046/j.1471-4159.1997.69020581.x
50. Liu Y Schubert D. 1997. Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis. Journal of Neurochemistry 69:2285–2293. doi: 10.1046/j.1471-4159.1997.69062285.x PMID: 9375659
51. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. 1994. Pancreatic islet cell toxicity of Amylin associated with type-2 diabetes mellitus. Nature 368:756–760. doi: 10.1038/368756a0 PMID: 8152488
52. Lorenzo A, Yankner BA. 1994. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. PNAS 91:12243–12247. doi: 10.1073/pnas.91.25.12243 PMID: 7991613
53. Luca S, Yau WM, Leapman R, Tycko R. 2007. Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry 46:13505–13522. doi: 10.1021/bi701427q PMID: 1797 9302
54. Madine J, Jack E, Stockley PG, Radford SE, Serpell LC, Middleton DA. 2008. Structural insights into the polymorphism of amyloid-like fibrils formed by region 20-29 of Amylin revealed by solid-state NMR and X-ray fiber diffraction. Journal of the American Chemical Society 130:14990–15001. doi: 10.1021/ja802483d PMID: 1 8937465
55. Magzoub M, Miranker AD. 2012. Concentration-dependent transitions govern the subcellular localization of islet amyloid polypeptide. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology 26:1228–1238. doi: 10.1096/fj.11-194613 PMID: 22183778
56. Maloy AL, Longnecker DS, Greenberg ER. 1981. The relation of islet amyloid to the clinical type of diabetes. Human Pathology 12:917–922. doi: 10.1016/S0046-8177(81)80197-9 PMID: 7028600
57. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. 2005. Likelihood-enhanced fast translation functions. Acta Crystallographica Section D Biological Crystallography 61:458–464. doi: 10.1107/S0907444905001617 PMID: 15805601
58. McCoy AJ. 2007. Solving structures of protein complexes by molecular replacement with phaser. Acta Crystallographica. Section D, Biological Crystallography 63:32–41. doi: 10.1107/S0907444906045975 PMID: 17164524
59. Meier DT, Entrup L, Templin AT, Hogan MF, Mellati M, Zraika S, Hull RL, Kahn SE. 2016. The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets. Diabetologia 59:2166–2171. doi: 10.1007/s00125-016-4045-x PMID: 27393137
60. Meier JJ, Kayed R, Lin C-Y, Gurlo T, Haataja L, Jayasinghe S, Langen R, Glabe CG, Butler PC. 2006. Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. AJP: Endocrinology and Metabolism 291:E1317–E1324. doi: 10.1152/ajpendo.00082.2006
61. Meng F Abedini A, Plesner A, Verchere CB, Raleigh DP. 2010. The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry 49:8127–8133. doi: 10.1021/bi100939a PMID: 20707388
62. Mirecka EA, Feuerstein S, Gremer L, Schröder GF, Stoldt M, Willbold D, Hoyer W. 2016. β-hairpin of islet amyloid polypeptide bound to an aggregation inhibitor. Scientific Reports 6:33474. doi: 10.1038/srep33474
63. Moriarty DF Raleigh DP. 1999. Effects of sequential proline substitutions on amyloid formation by human amylin20–29. Biochemistry 38:1811–1818. doi: 10.1021/bi981658g PMID: 10026261
64. Morita S, Sakagashira S, Ueyama M, Shimajiri Y, Furuta M, Sanke T. 2011. Progressive deterioration of insulin secretion in japanese type 2 diabetic patients in comparison with those who carry the S20G mutation of the islet amyloid polypeptide gene: A long-term follow-up study. Journal of Diabetes Investigation 2:287–292. doi: 10.1111/j.2040-1124.2011.00102.x PMID: 24843500
65. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65:55–63. doi: 10.1016/0022-1759(83)90303-4 PMID: 6606682
66. Mukherjee A, Morales-Scheihing D, Butler PC, Soto C. 2015. Type 2 diabetes as a protein misfolding disease. Trends in Molecular Medicine 21:439–449. doi: 10.1016/j.molmed.2015.04.005 PMID: 25998900
67. Mulder H, Ling C. 2009. Mitochondrial dysfunction in pancreatic beta-cells in type 2 diabetes. Molecular and Cellular Endocrinology 297:34–40. doi: 10.1016/j.mce.2008.05.015 PMID: 18606489
68. Nannenga BL, Shi D, Hattne J, Reyes FE, Gonen T. 2014a. Structure of catalase determined by MicroED. eLife 3: e03600. doi: 10.7554/eLife.03600 PMID: 25303172
69. Nannenga BL, Shi D, Leslie AG, Gonen T. 2014b. High-resolution structure determination by continuous-rotation data collection in MicroED. Nature Methods 11:1–5. doi: 10.1038/nmeth.3043 PMID: 25086503
70. Nelson R, Sawaya MR, Balbirnie M, Madsen AØ, Riekel C, Grothe R, Eisenberg D. 2005. Structure of the cross-beta spine of amyloid-like fibrils. Nature 435:773–778. doi: 10.1038/nature03680 PMID: 15944695
71. Nielsen JT, Bjerring M, Jeppesen MD, Pedersen RO, Pedersen JM, Hein KL, Vosegaard T, Skrydstrup T, Otzen DE, Nielsen NC. 2009. Unique identification of supramolecular structures in amyloid fibrils by solid-state NMR spectroscopy. Angewandte Chemie International Edition 48:2118–2121. doi: 10.1002/anie.200804198
72. Nishi M Chan SJ, Nagamatsu S, Bell GI, Steiner DF. 1989. Conservation of the sequence of islet amyloid polypeptide in five mammals is consistent with its putative role as an islet hormone. PNAS 86:5738–5742. doi: 10.1073/pnas.86.15.5738 PMID: 2668946
73. O’Brien TD, Butler PC, Kreutter DK, Kane LA, Eberhardt NL. 1995. Human islet amyloid polypeptide expression in COS-1 cells. A model of intracellular amyloidogenesis. The American Journal of Pathology 147:609–616. PMID: 7677175
74. Opie EL. 1901. The relation oe diabetes mellitus to lesions of the pancreas. hyaline degeneration of the islands OE langerhans. Journal of Experimental Medicine 5:527–541. doi: 10.1084/jem.5.5.527 PMID: 19866956
75. Oskarsson ME, Singh K, Wang J, Vlodavsky I, Li JP, Westermark GT. 2015. Heparan sulfate proteoglycans are important for islet amyloid formation and islet amyloid Polypeptide-induced apoptosis. The Journal of Biological Chemistry 290:15121–15132. doi: 10.1074/jbc.M114.631697 PMID: 25922077
76. Paulsson JF, Schultz SW, Köhler M, Leibiger I, Berggren P-O, Westermark GT. 2008. Real-time monitoring of apoptosis by caspase-3-like protease induced FRET reduction triggered by amyloid aggregation. Experimental Diabetes Research 2008:1–12. doi: 10.1155/2008/865850
77. Pilkington EH Gurzov EN, Kakinen A, Litwak SA, Stanley WJ, Davis TP, Ke PC. 2016. Pancreatic β-Cell membrane fluidity and toxicity induced by human islet amyloid polypeptide species. Scientific Reports 6:21274. doi: 10.1038/srep21274 PMID: 26880502
78. Richards FM. 1977. Areas, volumes, packing, and protein structure. Annual Review of Biophysics and Bioengineering 6:151–176. doi: 10.1146/annurev.bb.06.060177.001055
79. Ritzel RA Meier JJ, Lin CY, Veldhuis JD, Butler PC. 2007. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 56:65–71. doi: 10.2337/db06-0734 PMID: 17192466
80. Roberts AN, Leighton B, Todd JA, Cockburn D, Schofield PN, Sutton R, Holt S, Boyd Y, Day AJ, Foot EA. 1989. Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. PNAS 86:9662–9666. doi: 10.1073/pnas.86.24.9662 PMID: 2690069
81. Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang M, Jiang L, Arbing MA, Nannenga BL, Hattne J, Whitelegge J, Brewster AS, Messerschmidt M, Boutet S, Sauter NK, Gonen T, et al. 2015. Structure of the toxic core of α-synuclein from invisible crystals. Nature 525: 486–490. doi: 10.1038/nature15368 PMID: 26352473
82. Sakagashira S, Hiddinga HJ, Tateishi K, Sanke T, Hanabusa T, Nanjo K, Eberhardt NL. 2000. S20G mutant Amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type Amylin. The American Journal of Pathology 157:2101–2109. doi: 10.1016/S0002-9440(10)64848-1 PMID: 11106582
83. Sakagashira S, Sanke T, Hanabusa T, Shimomura H, Ohagi S, Kumagaye KY, Nakajima K, Nanjo K. 1996. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 45:1279–1281. doi: 10.2337/diab.45.9.1279 PMID: 8772735
84. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJ, McFarlane HT, Madsen AØ, Riekel C, Eisenberg D. 2007. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447:453–457. doi: 10.1038/nature05695 PMID: 17468747
85. Schlamadinger DE, Miranker AD. 2014. Fiber-dependent and -independent toxicity of islet amyloid polypeptide. Biophysical Journal 107:2559–2566. doi: 10.1016/j.bpj.2014.09.047 PMID: 25468335
86. Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H. 1995. Amyloid peptides are toxic via a common oxidative mechanism. PNAS 92:1989–1993. doi: 10.1073/pnas.92.6.1989 PMID: 7892213
87. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, et al. 2016. The antibody aducanumab reduces aβ plaques in Alzheimer’s disease. Nature 537:50–56. doi: 10.1038/nature19323 PMID: 27582220
88. Shi D, Nannenga BL, de la Cruz MJ, Liu J, Sawtelle S, Calero G, Reyes FE, Hattne J, Gonen T. 2016. The collection of MicroED data for macromolecular crystallography. Nature Protocols 11:895–904. doi: 10.1038/nprot.2016.046 PMID: 27077331
89. Shi D, Nannenga BL, Iadanza MG, Gonen T. 2013. Three-dimensional electron crystallography of protein microcrystals. eLife 2:e01345. doi: 10.7554/eLife.01345 PMID: 24252878
90. Sievers SA, Karanicolas J, Chang HW, Zhao A, Jiang L, Zirafi O, Stevens JT, Münch J, Baker D, Eisenberg D. 2011. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 475:96–100. doi: 10.1038/nature10154 PMID: 21677644
91. Soriaga AB, Sangwan S, Macdonald R, Sawaya MR, Eisenberg D. 2016. Crystal structures of IAPP amyloidogenic segments reveal a novel packing motif of out-of-register beta sheets. The Journal of Physical Chemistry B 120: 5810–5816. doi: 10.1021/acs.jpcb.5b09981
92. Sunde M Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC. 1997. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. Journal of Molecular Biology 273:729–739. doi: 10.1006/jmbi.1997.1348 PMID: 9356260
93. Tenidis K, Waldner M, Bernhagen J, Fischle W, Bergmann M, Weber M, Merkle ML, Voelter W, Brunner H, Kapurniotu A. 2000. Identification of a Penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. Journal of Molecular Biology 295:1055–1071. doi: 10.1006/jmbi.1999.3422 PMID: 10656810
94. Tomasello MF, Sinopoli A, Attanasio F, Giuffrida ML, Campagna T, Milardi D, Pappalardo G. 2014. Molecular and cytotoxic properties of hIAPP17-29 and rIAPP17-29 fragments: a comparative study with the respective full-length parent polypeptides. European Journal of Medicinal Chemistry 81:442–455. doi: 10.1016/j.ejmech. 2014.05.038 PMID: 24859763
95. Verchere CB, D’Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE. 1996. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. PNAS 93:3492–3496. doi: 10.1073/pnas.93.8.3492 PMID: 8622964
96. Weirich F, Gremer L, Mirecka EA, Schiefer S, Hoyer W, Heise H. 2016. Structural characterization of fibrils from recombinant human islet amyloid polypeptide by Solid-State NMR: The central FGAILS segment is part of the β-Sheet core. PLoS One 11:e0161243. doi: 10.1371/journal.pone.0161243 PMID: 27607147
97. Westermark GT, Gebre-Medhin S, Steiner DF, Westermark P. 2000. Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Molecular Medicine 6:998–1007. PMID: 11474116
98. Westermark P, Andersson A, Westermark GT. 2011. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiological Reviews 91:795–826. doi: 10.1152/physrev.00042.2009 PMID: 21742788
99. Westermark P, Engström U, Johnson KH, Westermark GT, Betsholtz C. 1990. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. PNAS 87:5036–5040. doi: 10.1073/pnas.87.13.5036 PMID: 2195544
100. Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH. 1987. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. PNAS 84:3881–3885. doi: 10.1073/pnas.84.11.3881 PMID: 3035556
101. Wiltzius JJ, Landau M, Nelson R, Sawaya MR, Apostol MI, Goldschmidt L, Soriaga AB, Cascio D, Rajashankar K, Eisenberg D. 2009a. Molecular mechanisms for protein-encoded inheritance. Nature Structural & Molecular Biology 16:973–978. doi: 10.1038/nsmb.1643 PMID: 19684598
102. Wiltzius JJ, Sievers SA, Sawaya MR, Cascio D, Popov D, Riekel C, Eisenberg D. 2008. Atomic structure of the cross-beta spine of islet amyloid polypeptide (amylin). Protein Science : A Publication of the Protein Society 17: 1467–1474. doi: 10.1110/ps.036509.108 PMID: 18556473
103. Wiltzius JJ, Sievers SA, Sawaya MR, Eisenberg D. 2009b. Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process. Protein Science : A Publication of the Protein Society 18:1521–1530. doi: 10.1002/pro.145 PMID: 19475663
104. Wineman-Fisher V, Atsmon-Raz Y, Miller Y. 2015. Orientations of residues along the β-arch of self-assembled Amylin fibril-like structures lead to polymorphism. Biomacromolecules 16:156–165. doi: 10.1021/bm501326y PMID: 25420121
105. Wu JW, Breydo L, Isas JM, Lee J, Kuznetsov YG, Langen R, Glabe C. 2010. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. The Journal of Biological Chemistry 285:6071–6079. doi: 10.1074/jbc.M109.069542 PMID: 20018889
106. Young LM, Saunders JC, Mahood RA, Revill CH, Foster RJ, Tu LH, Raleigh DP, Radford SE, Ashcroft AE. 2015. Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry. Nature Chemistry 7:73–81. doi: 10.1038/nchem.2129 PMID: 25515893
107. Yu L, Lee SJ, Yee VC. 2015. Crystal structures of polymorphic prion protein β1 peptides reveal variable steric zipper conformations. Biochemistry 54:3640–3648. doi: 10.1021/acs.biochem.5b00425 PMID: 25978088
108. Zraika S, Hull RL, Verchere CB, Clark A, Potter KJ, Fraser PE, Raleigh DP, Kahn SE. 2010. Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia 53:1046–1056. doi: 10.1007/s00125-010-1671-6 PMID: 20182863